Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;44(4):488-496.
doi: 10.1080/00952990.2018.1458234. Epub 2018 Apr 19.

Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment

Celestina Barbosa-Leiker  1   2   3 , Sterling McPherson  2   3   4 , Matthew E Layton  2   3   4 , Ekaterina Burduli  2   3   4 , John M Roll  2   3   4 , Walter Ling  5   6
Affiliations

Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment

Celestina Barbosa-Leiker et al. Am J Drug Alcohol Abuse. 2018.

Abstract

Background: There are sex differences in buprenorphine/naloxone clinical trials for opioid use. While women have fewer opioid-positive urine samples, relative to men, a significant decrease in opioid-positive samples was found during treatment for men, but not women. In order to inform sex-based approaches to improve treatment outcomes, research is needed to determine if opioid use, and predictors of opioid use, differs between men and women during treatment.

Objectives: To test for sex differences in opioid use during a buprenorphine/naloxone clinical trial and determine if sex differences exist in the associations between addiction-related problem areas and opioid use over the course of the trial.

Method: This secondary data analysis of the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003 examined sex differences (men = 347, women = 169) in opioid-positive samples in a randomized clinical trial comparing 7-day vs. 28-day buprenorphine/naloxone tapering strategies. Addiction-related problem areas were defined by Addiction Severity-Lite (ASI-L) domain composite scores.

Results: Women were more likely than men to use opioids during the course of the buprenorphine/naloxone clinical trial (B = .33, p = .01) and medical issues were positively related to submitting an opioid-positive sample during treatment for women (B = 1.67, p = .01). No ASI-L domain composite score was associated with opioid-positive samples during treatment for men.

Conclusion: Women were more likely than men to use opioids during the course of the buprenorphine/naloxone clinical trial, and medical issues predicted opioid use during treatment for women but not men. Complementary treatment for medical problems during opioid replacement therapy may benefit women.

Keywords: Opioid dependence; addiction severity index; buprenorphine/naloxone; sex differences.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percent of opioid-positive urine samples for the total sample and by sex.
Figure 2.
Figure 2.
Schematic representation of the linear latent growth model of opioid-positive urinalysis (opioid+UA) over time in a randomized clinical trial that compared buprenorphine/naloxone tapering strategies (7-day and 28-day). Intercept and slope parameters are constrained to indicate the linear model.
Figure 3.
Figure 3.
Schematic representation or primary results of the linear latent growth model of opioid-positive urinalysis (opioid+UA) over time in a randomized clinical trial that compared buprenorphine/naloxone tapering strategies (7-day and 28-day) in the female sample. Unstandardized regression coefficients are reported. ASI-L = Addiction Severity Index-Lite; *p<.05; ns statistically non-significant.
Figure 4.
Figure 4.
Schematic representation or primary results of the linear latent growth model of opioid-positive urinalysis (opioid+UA) over time in a randomized clinical trial that compared buprenorphine/naloxone tapering strategies (7-day and 28-day) in the male sample. Unstandardized regression coefficients are reported. ASI-L = Addiction Severity Index-Lite; *p<.05; ns statistically non-significant.
See this image and copyright information in PMC

References

    1. Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16–4984, NSDUH Series H-51). 2016.
    1. Jones HE, Fitzgerald H, Johnson RE. Males and females differ in response to opioid agonist medications. The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2005;14(3):223–33. Epub 2005/07/16. - PubMed
    1. Back SE, Payne RL, Simpson AN, Brady KT. Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addictive behaviors. 2010;35(11):1001–7. Epub 2010/07/06. - PMC - PubMed
    1. CDC. Vital Signs: Prescription Painkiller Overdoses. A Growing Epidemic, Especially Among Women. July 2013; Available from: http://www.cdc.gov/vitalsigns/prescriptionpainkilleroverdoses/index.html.
    1. Kaiser Family Foundation. Opioid Overdose Deaths by Gender. 2017; Available from: http://www.kff.org/other/state-indicator/opioid-overdose-deaths-by-gende....

Publication types